The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets).
James J. Harding
No relevant relationships to disclose
Federica Catalanotti
No relevant relationships to disclose
Amin Yaqubie
No relevant relationships to disclose
Gregory C. McDermott
No relevant relationships to disclose
Romona Kersellius
No relevant relationships to disclose
Taha Merghoub
No relevant relationships to disclose
Richard D. Carvajal
No relevant relationships to disclose
Sandra P. D'Angelo
No relevant relationships to disclose
Mark Andrew Dickson
No relevant relationships to disclose
Gary K. Schwartz
No relevant relationships to disclose
Jedd D. Wolchok
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Michael F. Berger
No relevant relationships to disclose
David B. Solit
No relevant relationships to disclose
Paul B. Chapman
Consultant or Advisory Role - GlaxoSmithKline; Roche/Genentech
Research Funding - GlaxoSmithKline; Roche/Genentech